H1N1 백신 시장 보고서 : 백신 종류별, 시장 종류별, 지역별(2026-2034년)

The global H1N1 vaccines market size reached USD 4.0 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 5.7 Billion by 2034, exhibiting a growth rate (CAGR) of 3.87% during 2026-2034. The increasing healthcare concerns, significant medical advancements, improving healthcare systems, and rising awareness about the importance of H1N1 vaccines are some of the major factors propelling the market.

H1N1 vaccines, also known as influenza A (H1N1) vaccines, are designed to provide protection against the H1N1 strain of the influenza virus. This strain, commonly referred to as "swine flu," caused a global pandemic in 2009. H1N1 vaccines contain inactivated or weakened forms of the virus or its components, prompting the immune system to produce antibodies against the H1N1 strain. These vaccines help prevent infection and mitigate the spread of the virus. They are typically included in seasonal flu vaccine formulations to offer immunity against H1N1 along with other prevalent influenza strains.

The ongoing threat of influenza pandemics underscores the importance of effective vaccines to prevent the spread of the H1N1 virus which represents one of the key factors driving the growth of the H1N1 vaccines market across the globe. High transmission rates and the potential for severe illness drive the demand for vaccines to safeguard public health. The increasing awareness about vaccination benefits and government initiatives to promote immunization programs amplify vaccine adoption which is further contributing to the market growth. Public health campaigns and educational efforts also contribute to higher vaccination rates. Additionally, the global interconnectedness of populations intensifies the need for preventive measures. International travel and trade facilitate the rapid spread of infectious diseases, necessitating robust vaccination strategies. Furthermore, collaborations between pharmaceutical companies, research institutions, and health organizations drive innovation and ensure timely vaccine development. Regulatory support and streamlined approval processes encourage investment in vaccine research and production which is creating a positive outlook for the market across the globe.

H1N1 VACCINES MARKET TRENDS/DRIVERS:

Rise in pandemic preparedness

The rising threat of future pandemics drives governments, healthcare organizations, and individuals to prioritize vaccination as a preventive measure, which is driving the growth of the market. The increasing need to minimize disease transmission and protect vulnerable populations is fueling the demand for H1N1 vaccines. This, along with improving healthcare infrastructure and increasing healthcare budgets by governments of various nations is contributing to the market growth.

Rising public health initiatives

Governments and health authorities worldwide are increasingly launching public health campaigns to promote vaccination and raise awareness about the benefits of H1N1 vaccines which is influencing the market growth. These initiatives focus on educating the public, dispelling myths, and encouraging proactive vaccination to ensure widespread protection against the virus. These campaigns contribute to higher vaccine uptake rates and improved community immunity. Governments of various nations are also focused on improving public healthcare facilities, making them accessible to even the remotest regions and to the marginalized sections, which is facilitating the uptake of the vaccines.

Rise in global travel and connectivity

Increased international travel and connectivity facilitate the rapid spread of infectious diseases like H1N1 which is further propelling the demand for H1N1 vaccines. The interconnectedness of global populations emphasizes the importance of population-level immunity to curb transmission. H1N1 vaccines play a vital role in reducing the potential for cross-border outbreaks by offering protection to travelers and reducing the risk of importation and subsequent transmission.

H1N1 VACCINES INDUSTRY SEGMENTATION:

Breakup by Vaccine Type:

• Intramuscular
• Intranasal
• Intradermal

Intramuscular vaccines hold a proven track record of eliciting strong and durable immune responses. The muscle tissue provides an optimal environment for antigen presentation, which leads to effective immune activation and antibody production. This enhances the vaccine's ability to confer protection against H1N1 and other influenza strains. Intramuscular injections are a well-established and familiar method in healthcare settings. Healthcare professionals are experienced in administering vaccines via this route, ensuring accurate dosing and proper delivery. The IM route is suitable for a wide range of age groups, from children to adults. This universality makes IM-administered H1N1 vaccines versatile and applicable in mass vaccination campaigns. Intramuscular injections are commonly associated with vaccination, contributing to public acceptance. People are accustomed to receiving vaccines in this manner, leading to fewer barriers and higher compliance rates.

Breakup by Market Type:

• Public
• Private

H1N1 vaccines serve crucial roles in public health by providing protection against the H1N1 strain of influenza virus. They help prevent widespread outbreaks by building population immunity, reducing the virus's transmission potential. This safeguards vulnerable individuals, such as the elderly, young children, and those with compromised immune systems. H1N1 vaccines minimize illness severity and related complications, reducing hospitalizations, medical costs, and the burden on healthcare systems. By preventing severe cases, vaccines contribute to overall public health and well-being. The widespread H1N1 vaccination efforts contribute to community immunity or herd immunity, indirectly protecting those who cannot be vaccinated due to medical reasons. This collaborative defense limits the virus's spread within the population. Furthermore, H1N1 vaccines play a pivotal role in pandemic preparedness, as they form the foundation for rapid response to emerging influenza strains with pandemic potential.

Breakup by Region:

• North America
• Europe
• Asia Pacific
• Middle East and Africa
• Latin America

The report has also provided a comprehensive analysis of all the major regional markets, which include North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. According to the report, North America accounted for the largest market share.

In North America, the H1N1 vaccines market is driven by factors, including proactive public health initiatives, well-established vaccination programs, and a strong healthcare infrastructure. The memory of past outbreaks and pandemics, such as the 2009 H1N1 pandemic, has heightened awareness about the importance of vaccination. Robust healthcare systems, accessible medical facilities, and high levels of health literacy contribute to a culture of vaccination. Additionally, government support, regulatory frameworks, and public-private partnerships facilitate timely vaccine development, distribution, and administration. These factors collectively promote the demand for H1N1 vaccines, ensuring preparedness and protection against influenza outbreaks in North America.

COMPETITIVE LANDSCAPE:

Key players in the H1N1 vaccines market are actively engaged in several strategic initiatives to address the demand for effective vaccines and ensure public health preparedness. These companies focus on continuous research and development (R&D) to create vaccines with enhanced immunogenicity and broader coverage against H1N1 and related strains. Collaborations with research institutions and health authorities enable them to stay informed about evolving virus strains and pandemic potential. Moreover, key players invest in production scalability and efficiency to meet demand during outbreaks. They work closely with regulatory agencies to ensure vaccine safety, efficacy, and timely approvals. In addition, these companies engage in public health advocacy, promoting vaccination through education and awareness campaigns. Furthermore, collaborations with global health organizations, governments, and non-profit entities ensure equitable vaccine distribution, especially in regions with limited access to healthcare. By prioritizing innovation, safety, and accessibility, key players contribute to effective disease prevention and control in the H1N1 vaccines market.

The report has provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

• Abbott Laboratories
• AstraZeneca plc
• CPL Biologicals Pvt. Ltd
• CSL Limited
• Zoetis Inc.

Key Questions Answered in This Report

• 1.What was the size of the global H1N1 vaccines market in 2025?
• 2.What is the expected growth rate of the global H1N1 vaccines market during 2026-2034?
• 3.What are the key factors driving the global H1N1 vaccines market?
• 4.What has been the impact of COVID-19 on the global H1N1 vaccines market?
• 5.What is the breakup of the global H1N1 vaccines market based on the vaccine type?
• 6.What is the breakup of the global H1N1 vaccines market based on the market type?
• 7.What are the key regions in the global H1N1 vaccines market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global H1N1 Vaccines Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Breakup by Vaccines Type
• 5.5 Breakup by Market Type
• 5.6 Analysis of Key Brands
• 5.7 Breakup by Region
• 5.8 Market Forecast

6 Market Breakup by Vaccines Type

• 6.1 Intramuscular
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Intranasal
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast
• 6.3 Intradermal
  • 6.3.1 Market Trends
  • 6.3.2 Market Forecast

7 Market Breakup by Type

• 7.1 Public
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Private
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast

8 Market Breakup by Region

• 8.1 North America
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Europe
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Asia Pacific
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast
• 8.4 Middle East and Africa
  • 8.4.1 Market Trends
  • 8.4.2 Market Forecast
• 8.5 Latin America
  • 8.5.1 Market Trends
  • 8.5.2 Market Forecast

9 Analysis of Key Brand

• 9.1 Agripal
• 9.2 Fiuarix
• 9.3 Influgen
• 9.4 Influvac
• 9.5 Nasovac
• 9.6 Vaxigrip
• 9.7 Others

10 SWOT Analysis

• 10.1 Overview
• 10.2 Strengths
• 10.3 Weaknesses
• 10.4 Opportunities
• 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

• 12.1 Overview
• 12.2 Bargaining Power of Buyers
• 12.3 Bargaining Power of Suppliers
• 12.4 Degree of Competition
• 12.5 Threat of New Entrants
• 12.6 Threat of Substitutes

13 Price Analysis

• 13.1 Price Indicators
• 13.2 Price Structure
• 13.3 Margin Analysis

14 Industry Developments

• 14.1 Pipeline and New Product Launches
• 14.2 Mergers & Acquisitions and Partnerships

15 Competitive Landscape

• 15.1 Market Structure
• 15.2 Key Players
• 15.3 Profiles of Key Players
  • 15.3.1 Abbott Laboratories
    • 15.3.1.1 Company Overview
    • 15.3.1.2 Product Portfolio
    • 15.3.1.3 Financials
    • 15.3.1.4 SWOT Analysis
  • 15.3.2 AstraZeneca plc
    • 15.3.2.1 Company Overview
    • 15.3.2.2 Product Portfolio
    • 15.3.2.3 Financials
    • 15.3.2.4 SWOT Analysis
  • 15.3.3 CPL Biologicals Pvt. Ltd
    • 15.3.3.1 Company Overview
    • 15.3.3.2 Product Portfolio
  • 15.3.4 CSL Limited
    • 15.3.4.1 Company Overview
    • 15.3.4.2 Product Portfolio
    • 15.3.4.3 Financials
    • 15.3.4.4 SWOT Analysis
  • 15.3.5 Zoetis Inc.
    • 15.3.5.1 Company Overview
    • 15.3.5.2 Product Portfolio
    • 15.3.5.3 Financials
    • 15.3.5.4 SWOT Analysis